ES2013129A6 - Procedimiento de obtencion de una composicion farmaceutica a base de n-metil-n- (1-fenil -2- propil) -2- propinilamina. - Google Patents

Procedimiento de obtencion de una composicion farmaceutica a base de n-metil-n- (1-fenil -2- propil) -2- propinilamina.

Info

Publication number
ES2013129A6
ES2013129A6 ES8901101A ES8901101A ES2013129A6 ES 2013129 A6 ES2013129 A6 ES 2013129A6 ES 8901101 A ES8901101 A ES 8901101A ES 8901101 A ES8901101 A ES 8901101A ES 2013129 A6 ES2013129 A6 ES 2013129A6
Authority
ES
Spain
Prior art keywords
propinylamine
propil
methyl
procedure
obtaining
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES8901101A
Other languages
English (en)
Inventor
Manfred Karobath
Jorg Reinhardt
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Somerset Pharmaceuticals Inc
Original Assignee
Sandoz AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10634325&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2013129(A6) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sandoz AG filed Critical Sandoz AG
Publication of ES2013129A6 publication Critical patent/ES2013129A6/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

PROCEDIMIENTO DE OBTENCION DE UNA COMPOSICION FARMACEUTICA A BASE DE N-METIL-N-(1-FENIL-2-PROPIL)-2-PROPINILAMINA. COMPRENDE DISPERSAR LA SUSTANCIA ACTIVA N-METIL-N-(1-FENIL-2-PROPIL)-2-PROPINILAMINA, EN FORMA RACEMICA U OPTIMAMENTE ACTIVA O EN FORMA DE SUS SALES DE ADICION DE ACIDO FARMACEUTICAMENTE ACEPTABLES, EN UN GEL O POLIMERO SOLIDO, TAL COMO UN POLIMERO HIDROFILO. LA COMPOSICION ES UTIL PARA EL TRATAMIENTO DE LA ENFERMEDAD DE PARKINSON.
ES8901101A 1988-03-29 1989-03-29 Procedimiento de obtencion de una composicion farmaceutica a base de n-metil-n- (1-fenil -2- propil) -2- propinilamina. Expired - Lifetime ES2013129A6 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB888807504A GB8807504D0 (en) 1988-03-29 1988-03-29 Improvements in/relating to organic compounds

Publications (1)

Publication Number Publication Date
ES2013129A6 true ES2013129A6 (es) 1990-04-16

Family

ID=10634325

Family Applications (1)

Application Number Title Priority Date Filing Date
ES8901101A Expired - Lifetime ES2013129A6 (es) 1988-03-29 1989-03-29 Procedimiento de obtencion de una composicion farmaceutica a base de n-metil-n- (1-fenil -2- propil) -2- propinilamina.

Country Status (18)

Country Link
EP (1) EP0404807B1 (es)
JP (1) JP2533211B2 (es)
KR (1) KR0136870B1 (es)
AU (1) AU630088B2 (es)
CA (1) CA1336071C (es)
DE (1) DE68907406T2 (es)
ES (1) ES2013129A6 (es)
FI (1) FI895681A7 (es)
GB (1) GB8807504D0 (es)
GR (1) GR1003711B (es)
HU (1) HU207441B (es)
IE (1) IE62955B1 (es)
IL (1) IL89748A (es)
MY (1) MY105121A (es)
NZ (1) NZ228467A (es)
PT (1) PT90120B (es)
WO (1) WO1989009051A1 (es)
ZA (1) ZA892321B (es)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4861800A (en) * 1987-08-18 1989-08-29 Buyske Donald A Method for administering the drug deprenyl so as to minimize the danger of side effects
HU209605B (en) * 1991-04-15 1994-09-28 Chinoin Gyogyszer Es Vegyeszet Process for production of wather-free transdermal preparation
EP0593807A1 (en) * 1992-10-22 1994-04-27 LTS Lohmann Therapie-Systeme GmbH & Co. KG Patch for transdermal administration of volatile pharmaceutically active ingredients of chemically basic nature and a process for preparation
HUT63579A (en) * 1991-12-20 1993-09-28 Chinoin Gyogyszer Es Vegyeszet Process for producing double-phase pharmaceutical compositions suitable for treating diseases occurring during neurodegenerative processes
US5242950A (en) * 1992-04-23 1993-09-07 Somerset Pharmaceuticals, Inc. Treatment of macular degeneration
HU223042B1 (hu) * 1993-04-20 2004-03-01 Hexal Ag. Parkinson-kór kezelésére alkalmas hatóanyagot tartalmazó tapasz
EP0762877B1 (en) 1994-06-03 2001-03-21 THEJMDE Trust Meta substituted arylalkylamines and therapeutic and diagnostic uses thereof
HU223475B1 (hu) * 1994-10-24 2004-07-28 Chinoin Gyógyszer és Vegyészeti Termékek Gyára Rt. Selegilint tartalmazó liposzoma-készítmény és eljárás ennek előállítására
US6033682A (en) 1995-01-13 2000-03-07 Somerset Pharmaceuticals, Inc. S(+) desmethylselegiline and its use in therapeutic methods and pharmaceutical compositions
US6319954B1 (en) 1995-01-13 2001-11-20 Somerset Pharmaceuticals, Inc. S-(+)-desmethylselegiline and its use in the therapeutic methods and pharmaceutical compositions
US6299901B1 (en) 1995-01-13 2001-10-09 Somerset Pharmaceuticals, Inc. Methods and pharmaceutical compositions employing desmethylselegiline
US6348208B1 (en) 1995-01-13 2002-02-19 Somerset Pharmaceuticals, Inc. Methods and pharmaceutical compositions employing desmethylselegiline
CA2223588C (en) 1995-06-07 2004-01-06 Noven Pharmaceuticals, Inc. Transdermal compositions containing low molecular weight drugs which are liquid at room temperatures
US6316022B1 (en) 1995-06-07 2001-11-13 Noven Pharmaceuticals, Inc. Transdermal compositions containing low molecular weight drugs which are liquid at room temperatures
DE19533089C1 (de) 1995-09-07 1997-05-22 Hexal Ag Tacrin-Pflaster
DE19533772C1 (de) * 1995-09-12 1998-01-02 Hexal Ag Tacrin/Selegilin-Pflaster
IL119417A (en) * 1996-10-13 2003-02-12 Moshe Kushnir Pharmaceutical composition for transdermal administration of levodopa for parkinson's disease
US7150881B2 (en) * 1997-06-26 2006-12-19 Mylan Technologies, Inc. Adhesive mixture for transdermal delivery of highly plasticizing drugs
DK1063981T3 (da) 1998-03-16 2002-10-14 Somerset Pharmaceuticals Inc Anvendelse af selegilin eller desmethylselegilin til behandling af sår, brandsår og dermatologiske skader
DE19814257A1 (de) * 1998-03-31 1999-10-07 Asta Medica Ag Brauseformulierungen
NZ525878A (en) † 1998-12-07 2004-12-24 Elan Pharma Int Ltd A method of treating nicotine dependance with mecamylamine
DE60231896D1 (de) 2001-11-05 2009-05-20 Krele Pharmaceuticals Llc Zusammensetzungen und verfahren zur erhöhung der compliance mit therapien unter verwendung von aldehyddehydrogenase-hemmern und zur behandlung von alkoholsmus
DE10338174A1 (de) 2003-08-20 2005-03-24 Lts Lohmann Therapie-Systeme Ag Transdermale Arzneimittelzubereitungen mit Wirkstoffkombinationen zur Behandlung der Parkinson-Krankheit
CA2588295C (en) 2004-11-23 2013-10-22 Adamas Pharma, Llc Method and composition for administering an nmda receptor antagonist to a subject
US7619007B2 (en) 2004-11-23 2009-11-17 Adamas Pharmaceuticals, Inc. Method and composition for administering an NMDA receptor antagonist to a subject
ATE481096T1 (de) 2005-04-06 2010-10-15 Adamas Pharmaceuticals Inc Verfahren und zusammensetzungen zur behandlung von zns-erkrankungen
US7846445B2 (en) 2005-09-27 2010-12-07 Amunix Operating, Inc. Methods for production of unstructured recombinant polymers and uses thereof
US7855279B2 (en) 2005-09-27 2010-12-21 Amunix Operating, Inc. Unstructured recombinant polymers and uses thereof
ES2409554T3 (es) * 2007-06-21 2013-06-27 Fujimoto Co., Ltd. Composición para administración transdérmica
JP2010536341A (ja) 2007-08-15 2010-12-02 アムニクス， インコーポレイテッド 生物学的に活性なポリペプチドの特性を改変するための組成物および方法
ES2610356T3 (es) 2009-02-03 2017-04-27 Amunix Operating Inc. Polipéptidos recombinantes extendidos y composiciones que comprenden los mismos
WO2010144508A1 (en) 2009-06-08 2010-12-16 Amunix Operating Inc. Glucose-regulating polypeptides and methods of making and using same
KR101813727B1 (ko) 2009-06-08 2018-01-02 아뮤닉스 오퍼레이팅 인코포레이티드 성장 호르몬 폴리펩타이드 및 이를 제조하고 사용하는 방법
CA2771999A1 (en) 2009-08-24 2011-03-10 Amunix Operating Inc. Coagulation factor vii compositions and methods of making and using same
CA2994873A1 (en) 2009-12-02 2011-06-09 Adamas Pharma, Llc Amantadine compositions and methods of use
ES2993140T3 (en) 2010-04-02 2024-12-23 Amunix Pharmaceuticals Inc Binding fusion proteins, binding fusion protein-drug conjugates, xten-drug conjugates and methods of making and using same
DE102010024105A1 (de) * 2010-06-17 2011-12-22 Grünenthal GmbH Transdermale Verabreichung von Memantin
EP2822577B1 (en) 2012-02-15 2019-02-06 Bioverativ Therapeutics Inc. Recombinant factor viii proteins
JP6256882B2 (ja) 2012-02-15 2018-01-10 アムニクス オペレーティング インコーポレイテッド 第ｖｉｉｉ因子組成物、ならびに組成物の作製方法および用途
US10154971B2 (en) 2013-06-17 2018-12-18 Adamas Pharma, Llc Methods of administering amantadine
TW202003554A (zh) 2013-08-14 2020-01-16 美商百歐維拉提夫治療公司 因子ｖｉｉｉ－ｘｔｅｎ融合物及其用途
EA201890423A1 (ru) 2015-08-03 2018-07-31 Биовератив Терапьютикс Инк. Слитые белки фактора ix, способы их получения и применения
WO2018071656A1 (en) 2016-10-14 2018-04-19 Knowles Enterprises Inc. Formulations for treatment of migraines
MX2019006444A (es) 2016-12-02 2019-10-30 Bioverativ Therapeutics Inc Métodos de tratamiento de artropatía hemofílica utilizando factores de coagulación quiméricos.
WO2018200885A1 (en) 2017-04-26 2018-11-01 Neurocentria, Inc. Magnesium compositions and methods of use
PL3793588T3 (pl) 2018-05-18 2025-09-01 Bioverativ Therapeutics Inc. Sposoby leczenia hemofilii a
KR20230041711A (ko) 2020-06-25 2023-03-24 아뮤닉스 파마슈티컬스, 인크. Her-2 표적화 이중특이적 조성물 및 이의 제조 및 사용 방법

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0139127A1 (en) * 1983-08-22 1985-05-02 F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft Transdermal drug delivery device and its preparation
IL72684A (en) * 1984-08-14 1989-02-28 Israel State Pharmaceutical compositions for controlled transdermal delivery of cholinergic or anticholinergic basic drugs
US4568343A (en) * 1984-10-09 1986-02-04 Alza Corporation Skin permeation enhancer compositions
DE3764144D1 (de) * 1986-04-16 1990-09-13 Asta Pharma Ag Synergistische kombination von amantadin und selegilin.

Also Published As

Publication number Publication date
EP0404807B1 (en) 1993-06-30
ZA892321B (en) 1990-12-28
PT90120A (pt) 1989-11-10
DE68907406D1 (de) 1993-08-05
IL89748A (en) 1993-07-08
AU3290089A (en) 1989-10-16
GR890100190A (el) 1990-01-19
AU630088B2 (en) 1992-10-22
FI895681A0 (fi) 1989-11-28
CA1336071C (en) 1995-06-27
IE62955B1 (en) 1995-02-20
KR900700089A (ko) 1990-08-11
HU207441B (en) 1993-04-28
GB8807504D0 (en) 1988-05-05
KR0136870B1 (ko) 1998-04-25
NZ228467A (en) 1991-12-23
HU892559D0 (en) 1990-01-28
EP0404807A1 (en) 1991-01-02
DE68907406T2 (de) 1993-10-14
IE890921L (en) 1989-09-29
HUT55220A (en) 1991-05-28
JP2533211B2 (ja) 1996-09-11
WO1989009051A1 (en) 1989-10-05
GR1003711B (el) 2001-10-25
PT90120B (pt) 1994-06-30
MY105121A (en) 1994-08-30
JPH02503677A (ja) 1990-11-01
FI895681A7 (fi) 1989-11-28

Similar Documents

Publication Publication Date Title
ES2013129A6 (es) Procedimiento de obtencion de una composicion farmaceutica a base de n-metil-n- (1-fenil -2- propil) -2- propinilamina.
MA23608A1 (fr) Forme de dosage ii d'unite multiple en comprime
DE3779500D1 (de) Levodopa-methyl-ester enthaltende pharmazeutische zusammensetzungen, ihre herstellung und therapeutische verwendungen.
PT87542A (pt) Process for the preparation of a medicament based on indolone derivatives for the treatment of the parkinson disease
CY1107711T1 (el) Υπογλωσσια χορηγηση φαρμακευτικης συνθεσης ως αγωγη εναντι οξεων διαταραχων
SE8800731L (sv) Fenylkarbamat
DE3579068D1 (de) Arzneimittelenthaltende matrizen fuer einfuehrungen in zonen mit cellularen lesionen.
FR2673538B1 (fr) Composition a base de 3-[2-(dimethylamino)ethyl]-n-methyl-1h-indole-5 methanesulfonamide pour l'administration buccale.
JP2007526794A5 (es)
ES2176234T3 (es) Sistema terapeutico transdermal con galantamina como componente activo.
HUP9904174A2 (hu) Bőrön át történő adagoláshoz szánt gyógyszerkészítmények
DK324687A (da) Transdermalt farmeceutisk praeparat
RU93032613A (ru) Фармацевтический препарат для лечения пациентов с пролонгированным временем коагуляции, способ лечения пациентов, применение epi ингибитора для получения фармацевтического препарата
ES2033682T3 (es) Procedimiento para preparar una composicion farmaceutica que contiene acido 2-(2-fluoro-4-bifenilil)propionico o una de sus sales.
MX9305248A (es) Compuestos de diarilpiperazinoacetamida.
ES2051733T3 (es) Procedimiento de obtencion de un medicamento a base de tamoxifen para uso local.
DK0412554T3 (da) Sustained-release-præparat til administration i hjernen
PT90308A (pt) Processo para a preparacao de composicoes farmaceuticas contendo azelastina com libertacao controlada da substancia activa
NO172043C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive n-2,3-butadienyl-triamioalkanderivater
SE9301877D0 (sv) In situ gel for therapeutic use
ES2043719T3 (es) Administracion de farmacos por via percutanea.
PE8798A1 (es) Procedimiento de separacion de los enantiomeros del 1-azabiciclo[2.2.2] octan-3-amina, 2-(difenilmetil) -n- [[2-metoxi-5-(1-metiletil) fenil] metil]
ATE227123T1 (de) Transdermales pflaster, das festes methylphenidat beinhaltet
PT742716E (pt) Composicao farmaceutica para administracao transdermica sistemica contendo a substancia activa morfina-6-glucuronido
FR2547730B1 (fr) Medicament hypolipidemiant contenant comme ingredient actif la d-3-acetoxy-cis-2,3-dihydro-5-(2-(dimethylamino)ethyl)-2-(p-methoxyphenyl)-1,5-benzothiazepine-4(5h)-one ou un de ses sels d'addition d'acides acceptables en pharmacie

Legal Events

Date Code Title Description
PC1A Transfer granted

Owner name: SOMERSET PHARMACEUTICALS INC.

FD1A Patent lapsed

Effective date: 20090330